A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR741 in Healthy Volunteers

Trial Profile

A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR741 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jan 2017

At a glance

  • Drugs SPR 741 (Primary)
  • Indications Gram-negative infections
  • Focus Adverse reactions; First in man
  • Sponsors Spero Therapeutics
  • Most Recent Events

    • 12 Jun 2016 New trial record
    • 08 Jun 2016 According to a Spero Therapeutics media release, the company plans to submit an Investigational New Drug (IND) application for its first SPR741 combination in 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top